SHERRON MILLER: Open Payments
NPI 1922352905 · HOLLYWOOD, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,858 in 159 payments from 10 companies in 2025. Trend: 2023 $996 · 2024 $3,235 · 2025 $3,858
Food & beverage: $3,851Education: $8
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $630 |
| Alkermes, Inc. | 19 | $624 |
| Neurocrine BioSciences, Inc. | 30 | $605 |
| Teva Pharmaceuticals USA, Inc. | 18 | $599 |
| Janssen Pharmaceuticals, Inc | 19 | $528 |
| ABBVIE INC. | 13 | $246 |
| Vanda Pharmaceuticals Inc. | 14 | $237 |
| Otsuka America Pharmaceutical, Inc. | 12 | $185 |
| E.R. Squibb & Sons, L.L.C. | 9 | $181 |
| Axsome Therapeutics, Inc. | 1 | $23 |
Products named: CAPLYTA, INGREZZA, INVEGA SUSTENNA, LYBALVI, AUSTEDO XR, UZEDY, ARISTADA, VRAYLAR.
Industry payments across FL — which companies pay providers there.
